Biotech Catalyst Heatmap

Interactive visual tool for scanning 200+ upcoming PDUFA dates, phase readouts, and earnings

Real-time updates • Color-coded by ODIN tier • Portfolio risk clustering

What is the Catalyst Heatmap?

The PDUFA.BIO Catalyst Heatmap is an interactive calendar view showing 200+ upcoming biotech catalyst events over the next 12 months. Instead of scrolling through a text calendar, the heatmap displays each event as a colored square, allowing you to instantly visualize:

  • Which events are coming up
  • Which ones have highest/lowest approval probability (via ODIN tier color)
  • How clustered catalysts are on specific dates (portfolio risk compression)
  • Which sectors (oncology, rare disease, etc.) dominate each quarter

This visual approach is faster than searching a spreadsheet and helps traders identify portfolio concentration risk and sector rotation opportunities.

Color Coding & ODIN Tiers

GREEN (TIER_1/2)

High confidence approvals. 80-93%+ accuracy. Low volatility runup potential. Best candidates for catalyst trading.

YELLOW (TIER_3)

Mixed signals. 60% accuracy. Moderate volatility. Use for sector rotation, avoid as primary positions.

RED (TIER_4)

High risk rejections. <50% accuracy. Avoid for runup trading. Use for short thesis research only.

Key Use Cases

Portfolio Scanning

Quickly scan your holdings for upcoming catalysts in the next 30-60 days. Identify which positions will have binary events and adjust exposure accordingly. The heatmap shows you at a glance if Q2 is catalyst-heavy vs quiet.

Sector Rotation

Look for quarter-to-quarter shifts in catalyst clusters. Example: Q1 is heavy oncology, Q3 is rare disease. Rotate your biotech exposure accordingly. The heatmap reveals these macro trends in seconds.

Risk Clustering

Identify dates where 3-5+ catalysts cluster (e.g., 3 PDUFA decisions on July 21). This signals high IV volatility, wider bid-ask spreads, and potential gap risk. Avoid overconcentration on those dates.

How to Read the Heatmap

X-Axis (Weeks)

Horizontal rows represent weeks (Monday-Sunday). Scroll right to see 3-6 months ahead.

Y-Axis (Companies/Tickers)

Each row represents a company with upcoming catalysts. Tickers are sorted by market cap (large to small, top to bottom).

Cell Color & Density

Each colored square = one catalyst event. The deeper the color, the higher the ODIN confidence. Darker greens are TIER_1 (93%+ accuracy). Lighter greens are TIER_2 (80%). Same logic for yellow and red.

Hovering Over a Cell

Hover over any colored square to see: ticker, company name, catalyst type (PDUFA/Readout/Earnings), expected date, ODIN tier, and approval probability.

Frequently Asked Questions

Why is a catalyst gray (no color)?

Gray means ODIN hasn't yet assigned a tier (rare for major PDUFAs, more common for smaller companies or recent regulatory filings). As the event gets closer (T-30 days), ODIN generates a tier prediction and the cell turns green/yellow/red.

Can I filter by sector or ODIN tier?

Yes. Use the filter dropdowns above the heatmap to show only: oncology, rare disease, immunology, etc. You can also filter by TIER_1 only (to see highest confidence trades), or hide TIER_4 (to reduce noise). Filters work in real-time.

How often is the heatmap updated?

The heatmap updates in real-time as new PDUFA dates are announced by the FDA. ODIN tier predictions update daily as new price and options data arrives. If you see a date change or new ticker appear, the data was just published to our database.

PDUFA Calendar 2026What Is a PDUFA Date?ODIN EnginePricing & PlansQ1 Oncology PDUFAsGlossary

Important: PDUFA.BIO is not the FDA. ODIN scores are ML model outputs, not financial advice. All investing carries risk. Read full disclaimer →

PDUFA.BIO
Tue Mar 3, 2026
12 this week

Biotech Catalyst Heatmap

Visual heatmap of upcoming PDUFA dates, phase readouts & earnings. Color-coded by ODIN approval probability tier and grouped by therapeutic area, event type, or tier.

GROUP:
SIZE:
TIER 1
TIER 2
TIER 3
TIER 4
Oncology18 catalysts
DSKYF
94.1%
DSKYF
T-DXd (trastuzumab deruxtecan)
May 18, 2026
PDUFA
94.1%
MRK
MRK
Pembrolizumab combos
Jul 6, 2026
PH3
AZN
94.1%
AZN
Datopotamab deruxtecan (DATROWAY)
Jun 2, 2026
PDUFA
94.1%
BMY
92.8%
BMY
Opdivo (nivolumab)
Apr 8, 2026
PDUFA
92.8%
PFE
PFE
PF-06821497 (mevrometostat)
Dec 2, 2026
PH3
BMY
89.4%
BMY
Iberdomide (CC-220)
Aug 17, 2026
PDUFA
89.4%
ARVS
88.5%
ARVS
Vepdegestrant
Jun 5, 2026
PDUFA
88.5%
EXEL
87.7%
EXEL
Zanzalintinib + Atezolizumab
Dec 3, 2026
PDUFA
87.7%
CORT
87.4%
CORT
Relacorilant
Jul 11, 2026
PDUFA
87.4%
LNTH
86.0%
LNTH
Gallium-68 edotreotide
Mar 29, 2026
PDUFA
86.0%
KURA
84.7%
KURA
Tipifarnib
Jul 1, 2026
PDUFA
84.7%
ORCA
81.7%
ORCA
Orca-T
Apr 6, 2026
PDUFA
81.7%
DCPH
81.4%
DCPH
Tirabrutinib
Dec 18, 2026
PDUFA
81.4%
NUVL
75.0%
NUVL
Zidesamtinib
Sep 18, 2026
PDUFA
75.0%
Private
73.8%
Private
177Lu-edotreotide
Aug 28, 2026
PDUFA
73.8%
REPL
70.2%
REPL
RP1 (vusolimogene oderparepvec) + Nivolumab
Apr 10, 2026
PDUFA
70.2%
Private
35.1%
Private
Tabelecleucel
Oct 10, 2026
PDUFA
35.1%
SMMT
25.2%
SMMT
Ivonescimab
Nov 14, 2026
PDUFA
25.2%
Rare Disease11 catalysts
REGN
94.6%
REGN
Garetosmab
Aug 15, 2026
PDUFA
94.6%
REGN
REGN
Mibavademab
Jul 14, 2026
PH3
BMRN
BMRN
Vosoritide
Aug 1, 2026
PH3
RARE
89.5%
RARE
DTX401 (pariglasgene autotemcel)
Aug 23, 2026
PDUFA
89.5%
ASNDSOON
88.0%
ASND
Navepegritide (TransCon CNP)
Feb 28, 2026
PDUFA
88.0%
BRNC
85.9%
BRNC
Adrabetadex
Aug 17, 2026
PDUFA
85.9%
RARE
RARE
GTX-102
Jul 15, 2026
PH3
DNLI
75.2%
DNLI
Tividenofusp alfa
Apr 5, 2026
PDUFA
75.2%
SRRK
SRRK
Apitegromab
Nov 1, 2026
PH3
RCKT
47.4%
RCKT
Kresladi (marnetegragene autotemcel)
Mar 28, 2026
PDUFA
47.4%
CAPR
7.3%
CAPR
CAP-1002 (deramiocel)
Aug 6, 2026
PDUFA
7.3%
Immunology10 catalysts
AMGN
AMGN
Dazodalibep
Sep 2, 2026
PH3
JNJ
93.7%
JNJ
Icotrokinra
Dec 1, 2026
PDUFA
93.7%
BMYSOON
90.7%
BMY
Deucravacitinib (Sotyktu)
Mar 6, 2026
PDUFA
90.7%
ARGX
90.7%
ARGX
Vyvgart (efgartigimod alfa-fcab)
May 10, 2026
PDUFA
90.7%
HBIO
82.3%
HBIO
Imlifidase (IDEFIRIX)
Aug 18, 2026
PDUFA
82.3%
VRDN
79.4%
VRDN
Veligrotug
Jun 30, 2026
PDUFA
79.4%
AZN
AZN
Benralizumab
Oct 6, 2026
PH3
VRDN
VRDN
VRDN-003
Jul 15, 2026
PH3
ARGX
ARGX
Efgartigimod PH20 SC
Oct 1, 2026
PH3
ARGX
ARGX
Efgartigimod PH20 SC
Dec 1, 2026
PH3
CNS9 catalysts
LLY
95.5%
LLY
Lecanemab SC Autoinjector (Leqembi)
May 24, 2026
PDUFA
95.5%
TAK
91.8%
TAK
Oveporexton (TAK-861)
Sep 1, 2026
PDUFA
91.8%
UCBJY
UCBJY
Fenfluramine
Sep 3, 2026
PH3
BMY
BMY
Cobenfy (xanomeline-trospium)
Jun 1, 2027
PH3
AXSM
78.9%
AXSM
AXS-05 (dextromethorphan/bupropion)
Apr 30, 2026
PDUFA
78.9%
CING
65.1%
CING
CTx-1301 (dexmethylphenidate)
May 31, 2026
PDUFA
65.1%
ACHV
44.4%
ACHV
Cytisinicline
Jun 20, 2026
PDUFA
44.4%
HLUYY
HLUYY
Eptinezumab
Sep 5, 2026
PH3
HRMY
HRMY
Pitolisant
Jul 15, 2026
PH3
Dermatology4 catalysts
LLY
LLY
Lebrikizumab
Jul 15, 2026
PH3
INCY
INCY
Ruxolitinib Cream
Oct 9, 2026
PH3
GDRM
92.4%
GDRM
RelabotulinumtoxinA
Aug 15, 2026
PDUFA
92.4%
AMZL
85.2%
AMZL
Aminolevulinic acid + RhodoLED
Sep 28, 2026
PDUFA
85.2%
Cardiovascular4 catalysts
AZN
94.0%
AZN
Baxdrostat
May 15, 2026
PDUFA
94.0%
NVO
NVO
Ziltivekimab
Sep 3, 2026
PH3
NVO
NVO
Ziltivekimab
Oct 5, 2026
PH3
LXRX
LXRX
Sotagliflozin
Mar 1, 2027
PH3
GI/Hepatology3 catalysts
GSK
93.6%
GSK
Linerixibat
Mar 24, 2026
PDUFA
93.6%
AZN
AZN
Tezepelumab
Jul 14, 2026
PH3
MRK
MRK
Tulisokibart (IV+SC)
Aug 1, 2026
PH3
Vaccines3 catalysts
GSK
GSK
Varicella vaccine (investigational)
Jul 1, 2026
PH3
SNY
SNY
PCV21
Dec 1, 2026
PH3
MRNA
88.7%
MRNA
mRNA-1010 (Seasonal Influenza Vaccine)
Aug 5, 2026
PDUFA
88.7%
Metabolic/Endocrine3 catalysts
LLY
93.1%
LLY
Orforglipron
Apr 10, 2026
PDUFA
93.1%
BMRNSOON
92.0%
BMRN
PALYNZIQ (pegvaliase)
Feb 28, 2026
PDUFA
92.0%
RYTM
44.3%
RYTM
Imcivree (setmelanotide)
Mar 20, 2026
PDUFA
44.3%
Metabolic2 catalysts
NVO
89.9%
NVO
Awiqli (insulin icodec)
Sep 1, 2026
PDUFA
89.9%
NVO
89.9%
NVO
CagriSema
Oct 1, 2026
PDUFA
89.9%
Respiratory2 catalysts
SNY
SNY
Itepekimab
Dec 1, 2026
PH3
SVRA
87.1%
SVRA
Molbreevi (molgramostim)
Aug 22, 2026
PDUFA
87.1%
Nephrology3 catalysts
NVO
NVO
Semaglutide
Sep 1, 2026
PH2
VERA
47.8%
VERA
Atacicept
Jul 7, 2026
PDUFA
47.8%
TVTX
35.4%
TVTX
Sparsentan
Apr 13, 2026
PDUFA
35.4%
Ophthalmology2 catalysts
CHRSSOON
80.5%
CHRS
Idebenone
Feb 28, 2026
PDUFA
80.5%
ALDX
1.1%
ALDX
Reproxalap
Mar 16, 2026
PDUFA
1.1%
Infectious1 catalysts
INO
67.8%
INO
INO-3107
Oct 30, 2026
PDUFA
67.8%
Hematology1 catalysts
PHAR
15.7%
PHAR
Besremi (ropeginterferon alfa-2b)
Aug 30, 2026
PDUFA
15.7%
Earnings27 catalysts
EOLSSOON
EOLS
Q4 2025 Earnings
Mar 3, 2026
EARN
QSISOON
QSI
Q4 2025 Earnings
Mar 3, 2026
EARN
ARCTSOON
ARCT
Q4 2025 Earnings
Mar 3, 2026
EARN
SRRKSOON
SRRK
Q4 2025 Earnings
Mar 3, 2026
EARN
MASSSOON
MASS
Q4 2025 Earnings
Mar 3, 2026
EARN
SOPHSOON
SOPH
Q4 2025 Earnings
Mar 3, 2026
EARN
VSTMSOON
VSTM
Q4 2025 Earnings
Mar 4, 2026
EARN
VEEVSOON
VEEV
Q4 2025 Earnings
Mar 4, 2026
EARN
ICCCSOON
ICCC
Q4 2025 Earnings
Mar 4, 2026
EARN
OCGNSOON
OCGN
Q4 2025 Earnings
Mar 4, 2026
EARN
COOSOON
COO
Q4 2025 Earnings
Mar 5, 2026
EARN
PROFSOON
PROF
Q4 2025 Earnings
Mar 5, 2026
EARN
OPRXSOON
OPRX
Q4 2025 Earnings
Mar 5, 2026
EARN
TNGXSOON
TNGX
Q4 2025 Earnings
Mar 5, 2026
EARN
HCMSOON
HCM
Q4 2025 Earnings
Mar 5, 2026
EARN
STXSSOON
STXS
Q4 2025 Earnings
Mar 9, 2026
EARN
BNTXSOON
BNTX
Q4 2025 Earnings
Mar 10, 2026
EARN
CTSO
CTSO
Q4 2025 Earnings
Mar 11, 2026
EARN
MOLN
MOLN
Q4 2025 Earnings
Mar 13, 2026
EARN
ACXP
ACXP
Q4 2025 Earnings
Mar 13, 2026
EARN
CATX
CATX
Q4 2025 Earnings
Mar 16, 2026
EARN
HQY
HQY
Q4 2025 Earnings
Mar 17, 2026
EARN
STIM
STIM
Q4 2025 Earnings
Mar 17, 2026
EARN
HTFL
HTFL
Q4 2025 Earnings
Mar 18, 2026
EARN
TNON
TNON
Q4 2025 Earnings
Mar 19, 2026
EARN
ABVX
ABVX
Q4 2025 Earnings
Mar 23, 2026
EARN
IPHA
IPHA
Q4 2025 Earnings
Mar 26, 2026
EARN
Phase 3 Readout54 catalysts
AARD
AARD
ARD-101 - (HERO)
Mar 11, 2026
RDOUT
KPTI
KPTI
Selinexor (XPORT-MF-034) - (SENTRY)
Mar 11, 2026
RDOUT
KPTI
KPTI
XPOVIO (selinexor), Pomalidomide and Dexamethasone - (EMN29/XPORT-MM-031)
Mar 11, 2026
RDOUT
KRYS
KRYS
KB803 - (IOLITE)
Mar 11, 2026
RDOUT
LLY
LLY
Orforglipron - (ACHIEVE-4)
Mar 11, 2026
RDOUT
MLTX
MLTX
Nanobody (sonelokimab) - (VELA-TEEN)
Mar 27, 2026
RDOUT
HRMY
HRMY
EPX-100 - (ARGUS)
Apr 1, 2026
RDOUT
VRDN
VRDN
VRDN-003 - (REVEAL-2)
Apr 1, 2026
RDOUT
ABVX
ABVX
Obefazimod - (ABTECT)
Apr 11, 2026
RDOUT
AZN
AZN
eplontersen - (CARDIO-TTRansform)
Apr 11, 2026
RDOUT
IONS
IONS
eplontersen - (CARDIO-TTRansform)
Apr 11, 2026
RDOUT
IONS
IONS
AKCEA-TTR-LRx - (CARDIO-TTRansform)
Apr 11, 2026
RDOUT
LPCN
LPCN
LPCN 1154 (oral brexanolone)
Apr 11, 2026
RDOUT
NTLA
NTLA
Lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) - (HAELO)
Apr 11, 2026
RDOUT
MRNA
MRNA
Trivalent (mRNA-1403) - (Nova 301)
Apr 14, 2026
RDOUT
OCUL
OCUL
AXPAXLI (OTX-TKI) - (SOL-1)
Apr 29, 2026
RDOUT
AZN
AZN
Imfinzi (durvalumab) - (VOLGA)
Apr 30, 2026
RDOUT
BNTX
BNTX
BNT323/DB-1303
May 11, 2026
RDOUT
EXEL
EXEL
XL092 with atezolizumab - (STELLAR-303)
May 11, 2026
RDOUT
GNLX
GNLX
Olvimulogene Nanivacirepvec (Olvi-Vec) - (OnPrime/GOG-3076)
Jun 11, 2026
RDOUT
RVMD
RVMD
Daraxonrasib (RMC-6236) - (RASolute 302)
Jun 11, 2026
RDOUT
AZN
AZN
Durvalumab in combination with monalizumab or oleclumab - (PACIFIC-9)
Jun 30, 2026
RDOUT
CELC
CELC
Gedatolisib with Fulvestrant - (VIKTORIA-1)
Jun 30, 2026
RDOUT
IPHA
IPHA
Durvalumab in combination with monalizumab or oleclumab - (PACIFIC-9)
Jun 30, 2026
RDOUT
JNJ
JNJ
NBTXR3 - (NANORAY-312)
Jun 30, 2026
RDOUT
LIAN
LIAN
NBTXR3 with Cetuximab - (NANORAY-312)
Jun 30, 2026
RDOUT
NBTX
NBTX
NBTXR3 with Cetuximab - (NANORAY-312)
Jun 30, 2026
RDOUT
RARE
RARE
GTX-102 - (Aspire)
Jul 11, 2026
RDOUT
SNGX
SNGX
HyBryte - (FLASH2)
Jul 11, 2026
RDOUT
JAZZ
JAZZ
Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01)
Jul 31, 2026
RDOUT
ONC
ONC
Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01)
Jul 31, 2026
RDOUT
ZYME
ZYME
Ziihera (zanidatamab-hrii) - (HERIZON-GEA-01)
Jul 31, 2026
RDOUT
KPTI
KPTI
XPOVIO (selinexor) - (XPORT-EC-042)
Aug 11, 2026
RDOUT
PHVS
PHVS
Deucrictibant (PHVS416) - (CHAPTER-3)
Aug 11, 2026
RDOUT
RNA
RNA
Delpacibart Etedesiran (del-desiran) - (HARBOR)
Aug 11, 2026
RDOUT
SLGL
SLGL
SGT-610 (patidegib)
Aug 11, 2026
RDOUT
HCM
HCM
ORPATHYS (savolitinib) and TAGRISSO (osimertinib) - (SANOVO)
Aug 30, 2026
RDOUT
NVS
NVS
MONJUVI (tafasitamab) - (frontMIND)
Sep 1, 2026
RDOUT
HCM
HCM
Sovleplenib - (China trial)
Sep 11, 2026
RDOUT
HCM
HCM
Sovleplenib - (ESLIM-02)
Sep 11, 2026
RDOUT
AZN
AZN
Datopotamab deruxtecan with or without osimertinib - (TROPION-Lung15)
Sep 30, 2026
RDOUT
EYPT
EYPT
DURAVYU (EYP-1901) - (LUCIA)
Oct 11, 2026
RDOUT
LLY
LLY
Jaypirca (pirtobrutinib) - (BRUIN CLL-322)
Oct 11, 2026
RDOUT
TENX
TENX
TNX-103 (oral levosimendan) - (LEVEL)
Oct 11, 2026
RDOUT
BMY
BMY
Milvexian - (Librexia AF)
Oct 31, 2026
RDOUT
JNJ
JNJ
Milvexian - (Librexia AF)
Oct 31, 2026
RDOUT
BMY
BMY
Milvexian - (Librexia STROKE)
Nov 11, 2026
RDOUT
CRVS
CRVS
Soquelitinib - (CPI-818)
Nov 11, 2026
RDOUT
JNJ
JNJ
Milvexian - (Librexia STROKE)
Nov 11, 2026
RDOUT
LLY
LLY
Orforglipron - (ATTAIN-OSA)
Nov 11, 2026
RDOUT
NVO
NVO
Zaltenibart - (OMS906)
Dec 11, 2026
RDOUT
OMER
OMER
Zaltenibart - (OMS906)
Dec 11, 2026
RDOUT
ADVM
ADVM
Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)
Dec 22, 2026
RDOUT
VIR
VIR
Tobevibart and Elebsiran - (ECLIPSE-1)
Dec 31, 2026
RDOUT
Phase 2 Readout58 catalysts
AVTX
AVTX
AVTX-009 (anti-IL-1β mAb) - (LOTUS)
Mar 11, 2026
RDOUT
NSRX
NSRX
NS002
Mar 11, 2026
RDOUT
CNTB
CNTB
Rademikibart - (Seabreeze STAT Asthma)
Apr 11, 2026
RDOUT
KPTI
KPTI
Selinexor (XPORT-MF-044) - (SENTRY-2)
Apr 11, 2026
RDOUT
OCS
OCS
OCS-01 - (DIAMOND-1)
Apr 11, 2026
RDOUT
LSTA
LSTA
Certepetide (LSTA1) - (BOLSTER)
Apr 18, 2026
RDOUT
LSTA
LSTA
LSTA1 in combination with SoC chemotherapy - (BOLSTER)
Apr 18, 2026
RDOUT
ALT
ALT
Pemvidutide - (RECLAIM)
May 11, 2026
RDOUT
BIIB
BIIB
IONIS-MAPTRx (ISIS 814907; BIIB080) - (CELIA)
May 14, 2026
RDOUT
IONS
IONS
IONIS-MAPTRx (ISIS 814907; BIIB080) - (CELIA)
May 14, 2026
RDOUT
BIVI
BIVI
Bezisterim (NE3107) - (ADDRESS-LC)
Jun 11, 2026
RDOUT
EWTX
EWTX
EDG-7500 - (CIRRUS-HCM)
Jun 11, 2026
RDOUT
MIRM
MIRM
Volixibat - (VISTAS)
Jun 11, 2026
RDOUT
QTTB
QTTB
Bempikibart - (SIGNAL-AA)
Jun 11, 2026
RDOUT
SYRE
SYRE
SPY001, SPY002, SPY003 - (SKYLINE)
Jun 11, 2026
RDOUT
ZBIO
ZBIO
Obexelimab - (SunStone)
Jun 11, 2026
RDOUT
WVE
WVE
WVE-N531 - (FORWARD-53)
Jun 27, 2026
RDOUT
DNTH
DNTH
DNTH103 - (MoMeNtum)
Jun 30, 2026
RDOUT
ENGN
ENGN
Detalimogene voraplasmid (EG-70) - (LEGEND)
Jun 30, 2026
RDOUT
LGVN
LGVN
Laromestrocel (lomecel-B) - (ELPIS II)
Jun 30, 2026
RDOUT
DWTX
DWTX
Halneuron - (HALT-CINP / HAL-CINP-203)
Jul 11, 2026
RDOUT
SION
SION
SION-719 - (PreciSION CF)
Jul 11, 2026
RDOUT
CANF
CANF
Namodenoson - (CF102-222PC)
Jul 15, 2026
RDOUT
MRK
MRK
Rezatapopt (PC14586) - (PYNNACLE)
Aug 15, 2026
RDOUT
PMVP
PMVP
Rezatapopt (PC14586) - (PYNNACLE)
Aug 15, 2026
RDOUT
BHVN
BHVN
Taldefgrobep alfa
Sep 11, 2026
RDOUT
EWTX
EWTX
Sevasemten (EDG-5509) - (GRAND CANYON)
Sep 11, 2026
RDOUT
NVS
NVS
TOUR006 - (spiriTED)
Sep 11, 2026
RDOUT
ORKA
ORKA
ORKA-001 - (EVERLAST-A)
Sep 11, 2026
RDOUT
PCSA
PCSA
NGC-Capecitabine (PCS6422)
Sep 11, 2026
RDOUT
PFE
PFE
Taldefgrobep alfa
Sep 11, 2026
RDOUT
SLN
SLN
Divesiran (SLN124) - (SANRECO)
Sep 11, 2026
RDOUT
SNDX
SNDX
Niktimvo (axatilimab-csfr) - (MAXPIRe)
Sep 11, 2026
RDOUT
TRML
TRML
TOUR006 - (spiriTED)
Sep 11, 2026
RDOUT
ABOS
ABOS
ACU193 - (ALTITUDE-AD)
Oct 11, 2026
RDOUT
RAPP
RAPP
RAP-219
Oct 11, 2026
RDOUT
RGNX
RGNX
Surabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ASCENT)
Oct 11, 2026
RDOUT
RNA
RNA
Delpacibart braxlosiran (del-brax) - (FORTITUDE)
Oct 11, 2026
RDOUT
ACRV
ACRV
ACR-368
Oct 31, 2026
RDOUT
ADAG
ADAG
muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98)
Oct 31, 2026
RDOUT
ANNX
ANNX
ANX007 - (ARCHER-II)
Oct 31, 2026
RDOUT
SYRE
SYRE
SPY072 - (SKYWAY-RD, basket study)
Oct 31, 2026
RDOUT
BNTX
BNTX
Autogene cevumeran (BNT122/RO7198457)
Nov 11, 2026
RDOUT
CRDF
CRDF
CRDF-004
Nov 11, 2026
RDOUT
ELTX
ELTX
ELI-002 - (AMPLIFY-7P)
Nov 11, 2026
RDOUT
PFE
PFE
CRDF-004
Nov 11, 2026
RDOUT
SKYE
SKYE
Nimacimab - (CBeyond)
Nov 20, 2026
RDOUT
ZNTL
ZNTL
Azenosertib (ZN-c3) + ZEJULA (Niraparib) - (DENALI)
Dec 1, 2026
RDOUT
ANRO
ANRO
ALTO-300
Dec 11, 2026
RDOUT
CLSD
CLSD
Surabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ATMOSPHERE)
Dec 11, 2026
RDOUT
CLYM
CLYM
Budoprutug (TNT119)
Dec 11, 2026
RDOUT
DMAC
DMAC
Rinvecalinase Alfa (DM199) - (ReMEDy2)
Dec 11, 2026
RDOUT
MGTX
MGTX
AAV2-hAQP1 - (AQUAx2)
Dec 11, 2026
RDOUT
RGNX
RGNX
Surabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ATMOSPHERE)
Dec 11, 2026
RDOUT
ROIV
ROIV
Mosliciguat - (PHocus)
Dec 11, 2026
RDOUT
NTHI
NTHI
NEO100-01
Dec 30, 2026
RDOUT
MNOV
MNOV
MN-001 (Tipelukast) - (NATG-202)
Dec 31, 2026
RDOUT
PBYI
PBYI
Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1)
Dec 31, 2026
RDOUT
Phase 1 Readout48 catalysts
ACIU
ACIU
[18F]ACI-15916 PET in α-synucleinopathies
Mar 11, 2026
RDOUT
BCYC
BCYC
Bicycle Toxin Conjugates zelenectide pevedotin (BT8009) - (Duravelo-2)
Mar 11, 2026
RDOUT
RLYB
RLYB
RLYB116
Mar 11, 2026
RDOUT
SEPN
SEPN
SEP-631
Mar 11, 2026
RDOUT
BNTX
BNTX
BNT323/DB-1303
Apr 11, 2026
RDOUT
IMMP
IMMP
IMP761
Apr 11, 2026
RDOUT
TNYA
TNYA
TN-401 - (RIDGE-1)
May 1, 2026
RDOUT
BMEA
BMEA
BMF-650 (GLP-131)
May 11, 2026
RDOUT
GLUE
GLUE
MRT-2359
May 11, 2026
RDOUT
MBX
MBX
MBX 4291
May 30, 2026
RDOUT
ACIU
ACIU
ACI-24 (anti-Abeta vaccine) - (ABATE)
Jun 11, 2026
RDOUT
ACIU
ACIU
ACI-24 (anti-Abeta vaccine)
Jun 11, 2026
RDOUT
BRNS
BRNS
VTP-1000 - (AVALON)
Jun 11, 2026
RDOUT
CLYD
CLYD
VTP-1000 - (AVALON)
Jun 11, 2026
RDOUT
SION
SION
SION-451 + Galicaftor (SION-2222)
Jun 11, 2026
RDOUT
TAK
TAK
ACI-24 (anti-Abeta vaccine) - (ABATE)
Jun 11, 2026
RDOUT
CLLS
CLLS
UCART22 - (BALLI-01)
Jun 30, 2026
RDOUT
HOWL
HOWL
WTX-124
Jul 1, 2026
RDOUT
PYXS
PYXS
PYX-201-101 - (MICVO)
Jul 11, 2026
RDOUT
BCYC
BCYC
BT5528 and OPDIVO (nivolumab)
Jul 31, 2026
RDOUT
BCYC
BCYC
BT7480 with nivolumab
Aug 11, 2026
RDOUT
KURA
KURA
ziftomenib in combination with gilteritinib (KOMET-008)
Aug 11, 2026
RDOUT
KYTX
KYTX
KYV-101
Aug 11, 2026
RDOUT
NCNA
NCNA
NUC-7738 (NuTide:701) in combination with pembrolizumab
Aug 11, 2026
RDOUT
ACRV
ACRV
ACR-2316
Aug 12, 2026
RDOUT
AZN
AZN
COM902 (AZD2936) - (ARTEMIDE-01)
Aug 18, 2026
RDOUT
CGEN
CGEN
COM902 (AZD2936) - (ARTEMIDE-01)
Aug 18, 2026
RDOUT
VSTM
VSTM
VS-6766 and defactinib - (RAMP 205)
Aug 31, 2026
RDOUT
DTIL
DTIL
ECUR-506 - (OTC-HOPE)
Sep 11, 2026
RDOUT
IRON
IRON
DISC-0974
Sep 11, 2026
RDOUT
ORIC
ORIC
Enozertinib (ORIC-114)
Sep 11, 2026
RDOUT
BMRN
BMRN
BMN 351
Sep 30, 2026
RDOUT
QURE
QURE
AMT-162
Sep 30, 2026
RDOUT
BCRX
BCRX
BCX17725
Oct 11, 2026
RDOUT
SDGR
SDGR
SGR-3515
Oct 31, 2026
RDOUT
ABCL
ABCL
ABCL575
Nov 11, 2026
RDOUT
APGE
APGE
APG279 (APG777+APG990)
Dec 11, 2026
RDOUT
BMY
BMY
RYZ101 - (ACTION-1)
Dec 11, 2026
RDOUT
CGEM
CGEM
CLN-978 - (OUTRACE SLE)
Dec 11, 2026
RDOUT
FDMT
FDMT
4D-710 - (AEROW)
Dec 11, 2026
RDOUT
IMMX
IMMX
NXC-201 (HBI10101) - (NEXICART-2)
Dec 11, 2026
RDOUT
LXEO
LXEO
LX2020 - (HEROIC-PKP2)
Dec 11, 2026
RDOUT
NXTC
NXTC
LNCB74
Dec 11, 2026
RDOUT
PMN
PMN
PMN310 - (PRECISE-AD)
Dec 11, 2026
RDOUT
ZYME
ZYME
ZW191
Dec 11, 2026
RDOUT
TCRX
TCRX
TSC-202-A0201
Dec 30, 2026
RDOUT
GILD
GILD
IDE397 + Trodelvy (sacituzumab-govitecan-hziy)
Dec 31, 2026
RDOUT
IDYA
IDYA
IDE397 + Trodelvy (sacituzumab-govitecan-hziy)
Dec 31, 2026
RDOUT

PDUFA.BIO

FDA catalyst intelligence powered by the ODIN v1108 scoring engine. Trained on 2,200+ PDUFA decisions & 2,000+ phase readouts (2015–2026).

PLATFORM

LEARN

PDUFA.BIO is the data-driven FDA PDUFA calendar and biotech catalyst calendar built for quantitative investors. Track upcoming PDUFA dates for 2026, FDA drug approval action dates, and biotech earnings dates in a unified, filterable calendar. Learn what a PDUFA date is and how the ODIN AI scoring engine generates FDA approval probability scores. Use the biotech catalyst screener to filter by ticker, therapeutic area, and ODIN tier. Explore the PDUFA runup strategy and verify ODIN's accuracy on the verified track record page. Browse our biotech glossary and catalyst research hub.

DISCLAIMER: PDUFA.BIO is not affiliated with, endorsed by, or connected to the U.S. Food & Drug Administration (FDA) or any government agency. The name "PDUFA" refers to the Prescription Drug User Fee Act and is used descriptively. This site does not provide financial, investment, legal, or medical advice. PDUFA.BIO is not a registered investment advisor, broker-dealer, or financial planner. Probability scores are generated by machine-learning models based on historical data and publicly available information. These scores are statistical estimates, not predictions or guarantees of FDA action or securities performance. Past approval rates do not guarantee future results.

RISK WARNING: Investing in biotechnology and pharmaceutical securities involves substantial risk, including the risk of total loss of capital. Binary catalyst events (such as PDUFA dates) can result in extreme price volatility. You should not invest money you cannot afford to lose. Always consult with a qualified financial advisor before making investment decisions. PDUFA.BIO, its operators, contributors, and affiliates accept no responsibility or liability for any losses arising from use of this site.

© 2026 PDUFA.BIO — All rights reserved.Market data via FMP · Social data via LunarCrush